Sector
PharmaceuticalsOpen
₹321.1Prev. Close
₹321.1Turnover(Lac.)
₹35.91Day's High
₹321.1Day's Low
₹314.7552 Week's High
₹44952 Week's Low
₹163Book Value
₹129.14Face Value
₹5Mkt Cap (₹ Cr.)
927.96P/E
13.73EPS
22.97Divi. Yield
0Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 14.16 | 14.14 | 14.13 | 14.42 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 299.79 | 321.63 | 381.55 | 356.02 |
Net Worth | 313.95 | 335.77 | 395.68 | 370.44 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2019 |
---|---|---|---|---|
Revenue | 387.96 | 372.82 | 299.26 | 19.35 |
yoy growth (%) | 4.06 | 24.57 | 1,446.28 | 54.73 |
Raw materials | -144.19 | -123.64 | -82.67 | 0 |
As % of sales | 37.16 | 33.16 | 27.62 | 0 |
Employee costs | -59.36 | -57.49 | -50.03 | -5.67 |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2019 |
---|---|---|---|---|
Profit before tax | 42.56 | 63.22 | 47.54 | -25.64 |
Depreciation | -23.67 | -19.03 | -14.93 | -3.78 |
Tax paid | -12.32 | -11.26 | 16.12 | 22.97 |
Working capital | 15.97 | 18.66 | 5.68 | 214.15 |
Other operating items |
Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2019 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 4.06 | 24.57 | 1,446.28 | 54.73 |
Op profit growth | -18.97 | 34.86 | -1,216.24 | -33.65 |
EBIT growth | -26.46 | 21.59 | -790.19 | -24.49 |
Net profit growth | -41.81 | -18.37 | -2,484.03 | -88.94 |
Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|---|
Gross Sales | 469.48 | 335.66 | 349.94 | 398.52 | 377.29 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 469.48 | 335.66 | 349.94 | 398.52 | 377.29 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 11.82 | 11.81 | 8.6 | 8.14 | 8.25 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,647.35 | 92.29 | 3,95,254.45 | 2,000.46 | 0.97 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,493.2 | 78.03 | 1,72,374.06 | 667 | 0.46 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,483.15 | 24.33 | 1,19,795.19 | 1,485.4 | 1.08 | 4,254.47 | 397.41 |
Dr Reddys Laboratories Ltd DRREDDY | 1,326.4 | 20.69 | 1,10,689.83 | 1,200.7 | 0.6 | 5,546.3 | 345.79 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,167.95 | 56.27 | 1,07,213.01 | 474 | 1.01 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Executive Director
Satish Varma
Company Sec. & Compli. Officer
Srikant N Sharma
Executive Vice Chairman & WTD
Krishna Datla
Non Executive Director
Rajeshwari Datla
Executive Director
ANUPAMA DATLA DESAI
Independent Director
Rajashri Santosh Kumar Ojha
Managing Director
Prashant Nagre
Independent Director
Pramod Kasat
Chairman & Independent Directo
Pradeep Manjunath Chandan
Independent Director
Ramanand Mundkur
A-1501 DIL Complex Majiwada,
Ghodbunder Road Thane One,
Maharashtra - 400610
Tel: 91-22-66230800/888
Website: http://www.fermentabiotech.com
Email: srikant.sharma@dil.net; contact@dil.net
C-101 247 Park,
L B S Marg, Vikhroli West,
Mumbai-400083
Tel: 91-22-49186000
Website: www.linkintime.co.in
Email: paytm.ipo@linkintime.co.in
Summary
Fermenta Biotech Limited was formerly incorporated as Duphar-Interfran Limited in May, 1951. The Company name was changed to DIL Limited in September, 2003 and later on, the name was further changed t...
Read More
Reports by Fermenta Biotech Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.